Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 17,144 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers

dMAbs for Prevention of COVID-19

NCT05293249
Conditions
Healthy Volunteers
Interventions
dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
Combination Product · Drug
Lead sponsor
Pablo Tebas
Other
Eligibility
18 Years to 60 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Recurrent Platinum Resistant Ovarian Cancer
Interventions
VB-111 + Paclitaxel, Placebo + Paclitaxel
Drug
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
64
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 56 more
Conditions
Lung Cancer
Interventions
Best Practice, Cancer Educational Materials, Behavioral, Psychological or Informational Intervention, Counseling
Other · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
55 Years to 80 Years
Enrollment
2,355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Linkage to Care - Part I

NCT00703040
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Fort Lauderdale, Florida • Miami, Florida + 4 more
Terminated Not applicable Interventional

Trial of Feedback on Blood Use

NCT02232568
Conditions
Compliance With Restrictive RBC Transfusion Guideline
Interventions
Feedback
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 2 more
Completed Not applicable Interventional

Endovascular Engineering ENGULF Study

NCT05597891
Conditions
Pulmonary Embolism
Interventions
Hēlo PE Thombectomy System
Device
Lead sponsor
Endovascular Engineering
Industry
Eligibility
18 Years to 90 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
21
States / cities
Los Angeles, California • Pasadena, California • Torrance, California + 13 more
Conditions
Tumor, Solid
Interventions
Indocyanine Green
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Solid Tumors
Interventions
nesvacumab (REGN910/ SAR307746), aflibercept (ziv-aflibercept)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Indianapolis, Indiana • New York, New York • Oklahoma City, Oklahoma + 2 more
Conditions
Hypertension, Dyslipidemia
Interventions
Amlodipine/Atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 73 more
Completed Phase 1Phase 2 Interventional Results available

Study of MLN8237 in Combination With Irinotecan and Temozolomide

NCT01601535
Conditions
Neuroblastoma
Interventions
MLN8237, Irinotecan, Temozolomide
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
12 Months to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Conditions
SARS-CoV-2, Covid-19
Interventions
Sirolimus 1 MG/ML, Placebo
Drug
Lead sponsor
Walter K. Kraft
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Federal Aviation Administration (FAA) National Sleep Study

NCT05035940
Conditions
Noise Exposure
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Endometrial Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
Conditions
Idiopathic Short Stature
Interventions
Genotropin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 10 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
43
States / cities
Little Rock, Alaska • Little Rock, Arkansas • Los Angeles, California + 32 more
Conditions
Nephropathic Cystinosis
Interventions
DFT383
Genetic
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 5 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
6
States / cities
Phoenix, Arizona • San Diego, California • Stanford, California + 3 more
Conditions
Knee Osteoarthritis
Interventions
SM04690, Placebo, Sham
Drug · Other
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
74
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 68 more
Conditions
Obesity, Weight Gain, Diabetes Type 2
Interventions
Sugary drink warning labels
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Short Bowel Syndrome
Interventions
Placebo, Teduglutide 0.05 mg/kg/d, Teduglutide 0.1 mg/kg/d
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
14
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
Conditions
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
valproic acid
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
15
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more
Completed Not applicable Interventional Results available

Protocolized Care for Early Septic Shock

NCT00510835
Conditions
Sepsis, Severe Sepsis, Septic Shock
Interventions
Early Goal Directed Therapy (EGDT), Protocolized Standard Care (PSC), Usual Care (UC)
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
Conditions
Ulcerative Colitis and Crohn's Disease
Interventions
Vedolizumab, Other Biologic Agents
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 54 more
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1023
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
Conditions
Recurrent Osteosarcoma
Interventions
Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
149
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 90 more